OCREVUS®. Start Strong in First-Line. Stay Strong.1
Barcelona, Spain. 24–26 September.
OCREVUS®.
Start Strong in First-Line. Stay Strong.1
Barcelona, Spain. 24–26 September.
More information on Medically
How have MS therapies evolved over the last decade? Join our experts as they navigate the evolution of MS treatment, from anti-CD20s to future therapies!
Wednesday, 24 September | 13:15–14:15 | Lecture Hall 7
Start OCREVUS® 2 years earlier,
delay over 8 years of progression in RMS.2
Early treatment helps improve long-term outcomes in people with MS.2
SC, 10 minutes, twice–yearly.1,*
The quick dosing of OCREVUS® SC gives your patients more time for what matters most.1
The only anti-CD20 approved to use during
breastfeeding, supported by human data.1,3
Trusted by >420,000 RMS & PPMS patients.4
A trusted and safe option widely used worldwide.3,4
Roche: Advancing MS Care Through Innovation.5
Committed to advancing solutions to transform MS treatment possibilities.5
Start OCREVUS® 2 years earlier,
delay over 8 years of progression in RMS.2
Early treatment helps improve long-term outcomes in people with MS.2
Start OCREVUS® 2 years earlier, delay over 8 years of progression in RMS.2
Early treatment helps improve long-term outcomes in people with MS.2
SC, 10 minutes, twice–yearly.1,*
The quick dosing of OCREVUS® SC gives your patients more time for what matters most.1
The only anti-CD20 approved to use during
breastfeeding, supported by human data.1,3
Trusted by >420,000 RMS & PPMS patients.4
A trusted and safe option widely used worldwide.3,4
The only anti-CD20 approved to use during breastfeeding, supported by human data.1,3
Trusted by >420,000 RMS & PPMS patients.4
A trusted and safe option widely used worldwide.3,4
Roche: Advancing MS Care Through Innovation.5
Committed to advancing solutions to transform MS treatment possibilities.5
Prof. Xavier Montalban
Multiple Sclerosis Centre
of Catalonia (Cemcat),
Vall d’Hebron University Hospital,
Barcelona, Spain
Prof. Amit Bar-Or
Center for Neuroinflammation
and Neurotherapeutics and
Department of Neurology,
Perelman School of Medicine,
University of Pennsylvania,
Philadelphia, USA
Dr Riley Bove
Department of Neurology,
University of California,
San Francisco, USA
Dr Enric Monreal
MS Unit – Hospital Universitario Ramón y Cajal,
Madrid, Spain
Dr Jiwon Oh
St. Michael’s Hospital,
Toronto, Canada
Roche Polska Sp. z o.o.
ul. Domaniewska 28
02-672 Warszawa
tel.: +48 22 345 1888
fax: +48 22 345 1874
*Does not include all aspects of the treatment. Actual injection time may vary. Oral premedications are to be administered shortly before each injection with 20 mg of oral dexamethasone (or equivalent) and an oral antihistamine (e.g., desloratadine or equivalent). OCREVUS® SC is HCP-administered. For the initial dose, post-injection monitoring with access to appropriate medical support to manage severe reactions such as IRs (injection reactions), for at least one hour after injection is recommended. For subsequent doses, the need for post-injection monitoring is at the treating physician’s discretion.1
CD: Cluster of Differentiation; HCP: healthcare professional; MS: Multiple Sclerosis; PPMS: Primary Progressive Multiple Sclerosis; RMS: Relapsing Multiple Sclerosis; SC: Subcutaneous.
Abbreviated Product Information for Ocrevus is available at: go.roche.com/OcrevusAPI
References:
1. OCREVUS® (ocrelizumab) Summary of Product Characteristics.
2. Hauser SL, et al. The Patient Impact of 11 Years of Ocrelizumab Treatment in Multiple Sclerosis: Long-Term Data from the Phase III OPERA and ORATORIO Studies. Presented at ECTRIMS, 9–11 October 2024, Copenhagen, Denmark. P1664.
3. Yeh WZ, et al. Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies. Neurol Neuroimmunol Neuroinflamm 2024;11:e200328.
4. Roche Data on File. March 2025.
5. Roche Press Release. Available at: https://www.roche.com/solutions/focus-areas/neuroscience/multiple-sclerosis. Accessed August 2025.